Wed, December 21, 2011
Tue, December 20, 2011
[ Tue, Dec 20th 2011 ]: Market Wire
Bard Acquires Lutonix, Inc.
Mon, December 19, 2011
Sun, December 18, 2011
Sat, December 17, 2011
Fri, December 16, 2011
Thu, December 15, 2011
Wed, December 14, 2011
Tue, December 13, 2011
Mon, December 12, 2011

Arrowhead to Report Fiscal 2011 Fourth Quarter and Year-End Financial Results


//health-fitness.news-articles.net/content/2011/ .. urth-quarter-and-year-end-financial-results.html
Published in Health and Fitness on by Market Wire   Print publication without navigation



PASADENA, Calif.--([ ])--Arrowhead Research Corporation (NASDAQ:ARWR)today announced that it will report its financial results for the fiscal 2011 fourth quarter and year ended September 30, 2011, on Tuesday, December 20, 2011 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the conference call, please dial 877-317-6789 (toll free from the US and Canada), or 412-317-6789 (for international callers). Investors may also access a live audio webcast of this conference call on the Company's website at [ www.arrowheadresearch.com ].

A replay of the webcast will be available approximately two hours after the conclusion of the call. The webcast archive will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be made available until Tuesday, December 27, 2011. The audio replay can be accessed by dialing 877-344-7529 (toll free from the US and Canada), or 412-317-0088 (for international callers) and entering Event ID 10007838.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a clinical stage nanomedicine company developing innovative therapies at the interface of biology and nanoengineering. Arrowheadas world-class capabilities and intellectual property covering nucleic acid delivery, siRNA chemistry, and tissue targeting allow it to design and develop therapeutic agents for a wide range of diseases. The companyas lead products include CALAA-01, an oncology drug candidate based on the gene silencing RNA interference (RNAi) mechanism, and Adipotidea", an anti-obesity peptide that targets and kills the blood vessels that feed white adipose tissue. Arrowhead is leveraging its proprietary Dynamic PolyConjugatea" (DPC), Liposomal Nanoparticle (LNP), and RONDELa" delivery platforms to support its own pipeline of preclinical and clinical candidates and to secure external partnerships and collaborations with biotech and pharmaceutical companies. For more information, please visit [ www.arrowheadresearch.com ].


Publication Contributing Sources

Publication Sponsors
[ Last Sunday ] - Oceanside Rental Gear